Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

第2相 完了 NCT05834738

概要

The ASSIST study was a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).

Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 12

From Baseline to Week 12 · percentage change in UPCR

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoieti — GlaxoSmithKline
• Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
• Bone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine
• Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients — The University of Texas at Arlington
• Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver F — Genfit
• High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis. — University of Florida

すべての治験